Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables: 2023-2025

Historic Change in Receivables for Phathom Pharmaceuticals (PHAT) over the last 2 years, with Sep 2025 value amounting to $4.5 million.

  • Phathom Pharmaceuticals' Change in Receivables fell 55.44% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 65.01%. This contributed to the annual value of $37.2 million for FY2024, which is 2170.01% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Change in Receivables stood at $4.5 million for Q3 2025, which was down 69.55% from $14.9 million recorded in Q2 2025.
  • In the past 5 years, Phathom Pharmaceuticals' Change in Receivables registered a high of $17.7 million during Q4 2024, and its lowest value of -$2.4 million during Q1 2025.
  • In the last 3 years, Phathom Pharmaceuticals' Change in Receivables had a median value of $5.8 million in 2024 and averaged $7.0 million.
  • In the last 5 years, Phathom Pharmaceuticals' Change in Receivables soared by 984.00% in 2024 and then tumbled by 208.47% in 2025.
  • Phathom Pharmaceuticals' Change in Receivables (Quarterly) stood at $1.6 million in 2023, then soared by 984.00% to $17.7 million in 2024, then tumbled by 55.44% to $4.5 million in 2025.
  • Its Change in Receivables stands at $4.5 million for Q3 2025, versus $14.9 million for Q2 2025 and -$2.4 million for Q1 2025.